Access to highly active antiretroviral therapy (HAART) for women and children in the WHO European Region 2002-2006
- PMID: 20024746
- DOI: 10.1080/09540120802537872
Access to highly active antiretroviral therapy (HAART) for women and children in the WHO European Region 2002-2006
Abstract
Objective. To assess the level of access to highly active antiretroviral therapy (HAART) for women and children in the WHO European Region. Methods. Analysis of data from three national surveys of 53 WHO European Member States. The comparative level of access to HAART for women and children was assessed by comparing the percentage of reported HIV cases with the percentage of HAART recipients in women at the end of 2002 and 2006 and in children at the end of 2004 and 2006. Findings. Overall, the data suggest that there is equivalence of access to antiretroviral therapy by gender and age in Europe. However, in central and eastern Europe women were disproportionately more likely to receive HAART when compared with men in 2006, representing 29% of HIV cases when compared with 39% of HAART recipients in central Europe, and 34% of HIV cases when compared with 42% of HAART recipients in eastern Europe. In comparison with adults, children (<15 years of age) were over-represented among HAART recipients when compared with HIV cases in eastern Europe, accounting for 1% of HIV cases and 9% of people on HAART in 2004 and 1% of HIV cases and 8% HAART recipients in 2006. Conclusion. Access to HAART remains inequitable in terms of gender in central and eastern Europe, favouring women over men, and in terms of age in eastern Europe, favouring children over adults. Despite high and increasing coverage with HAART in many European countries, countries must address how to further increase the number of people on treatment while ensuring equitable access for all population groups in need.
Similar articles
-
Access to highly active antiretroviral therapy (HAART) in the WHO European Region 2003-2005.Scand J Public Health. 2008 Mar;36(2):183-9. doi: 10.1177/1403494807085191. Scand J Public Health. 2008. PMID: 18519283
-
Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004.Int J Drug Policy. 2007 Aug;18(4):271-80. doi: 10.1016/j.drugpo.2007.02.010. Epub 2007 Jun 21. Int J Drug Policy. 2007. PMID: 17689375
-
Inequalities in health: access to treatment for HIV/AIDS.Ann Ist Super Sanita. 2007;43(4):313-6. Ann Ist Super Sanita. 2007. PMID: 18209264 Review.
-
Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.Pediatr Infect Dis J. 2003 Oct;22(10):863-7. doi: 10.1097/01.inf.0000091282.70253.5f. Pediatr Infect Dis J. 2003. PMID: 14551485
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
Cited by
-
Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review.AIDS Res Hum Retroviruses. 2015 Jan;31(1):85-97. doi: 10.1089/AID.2014.0205. AIDS Res Hum Retroviruses. 2015. PMID: 25313793 Free PMC article.
-
Burden of HIV infection among children aged 18 months to 14 years in Kenya: results from a nationally representative population-based cross-sectional survey.J Acquir Immune Defic Syndr. 2014 May 1;66 Suppl 1(Suppl 1):S82-8. doi: 10.1097/QAI.0000000000000118. J Acquir Immune Defic Syndr. 2014. PMID: 24732823 Free PMC article.
-
Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study.BMC Infect Dis. 2012 Nov 12;12:293. doi: 10.1186/1471-2334-12-293. BMC Infect Dis. 2012. PMID: 23140254 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical